We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why the Earnings Streak Will Continue for ACADIA Pharmaceuticals (ACAD)
Read MoreHide Full Article
Looking for a stock that might be in a good position to beat earnings at its next report? Consider ACADIA Pharmaceuticals Inc. (ACAD - Free Report) , a firm in the Medical - Biomedical and Genetics industry, which could be a great candidate for another beat.
This company has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. In fact, in these reports, ACAD has beaten estimates by at least 15% in both cases, suggesting it has a nice short-term history of crushing expectations.
Earnings in Focus
Two quarters ago, ACAD was expected to post a loss of 71 cents per share, while it actually produced a loss of 55 cents per share, a beat of 22.5%. Meanwhile, for the most recent quarter, the company looked to deliver a loss of 63 cents per share, when it actually saw a loss of 53 cents per share instead, representing a 15.9% positive surprise.
ACADIA Pharmaceuticals Inc. Price and EPS Surprise
Thanks in part to this history, recent estimates have been moving higher for ACADIA Pharmaceuticals. In fact, the Earnings ESP for ACAD is positive, which is a great sign of a coming beat.
After all, the Zacks Earnings ESP compares the most accurate estimate to the broad consensus, looking to find stocks that have seen big revisions as of late, suggesting that analysts have recently become more bullish on the company’s earnings prospects. This is the case for ACAD, as the firm currently has a Zacks Earnings ESP of 4.03%, so another beat could be around the corner.
When you add this solid Zacks Rank to a positive Earnings ESP, a positive earnings surprise happens nearly 70% of the time, so it seems pretty likely that ACAD could see another beat at its next report, especially if recent trends are any guide.
Zacks Editor-in-Chief Goes "All In" on This Stock
Full disclosure, Kevin Matras now has more of his own money in one particular stock than in any other. He believes in its short-term profit potential and also in its prospects to more than double by 2019. Today he reveals and explains his surprising move in a new Special Report.
Image: Bigstock
Why the Earnings Streak Will Continue for ACADIA Pharmaceuticals (ACAD)
Looking for a stock that might be in a good position to beat earnings at its next report? Consider ACADIA Pharmaceuticals Inc. (ACAD - Free Report) , a firm in the Medical - Biomedical and Genetics industry, which could be a great candidate for another beat.
This company has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. In fact, in these reports, ACAD has beaten estimates by at least 15% in both cases, suggesting it has a nice short-term history of crushing expectations.
Earnings in Focus
Two quarters ago, ACAD was expected to post a loss of 71 cents per share, while it actually produced a loss of 55 cents per share, a beat of 22.5%. Meanwhile, for the most recent quarter, the company looked to deliver a loss of 63 cents per share, when it actually saw a loss of 53 cents per share instead, representing a 15.9% positive surprise.
ACADIA Pharmaceuticals Inc. Price and EPS Surprise
ACADIA Pharmaceuticals Inc. Price and EPS Surprise | ACADIA Pharmaceuticals Inc. Quote
Thanks in part to this history, recent estimates have been moving higher for ACADIA Pharmaceuticals. In fact, the Earnings ESP for ACAD is positive, which is a great sign of a coming beat.
After all, the Zacks Earnings ESP compares the most accurate estimate to the broad consensus, looking to find stocks that have seen big revisions as of late, suggesting that analysts have recently become more bullish on the company’s earnings prospects. This is the case for ACAD, as the firm currently has a Zacks Earnings ESP of 4.03%, so another beat could be around the corner.
This is particularly true when you consider that ACAD has a great Zacks Rank #2 (Buy), which can be a harbinger of outperformance and a signal for a strong earnings profile. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
When you add this solid Zacks Rank to a positive Earnings ESP, a positive earnings surprise happens nearly 70% of the time, so it seems pretty likely that ACAD could see another beat at its next report, especially if recent trends are any guide.
Zacks Editor-in-Chief Goes "All In" on This Stock
Full disclosure, Kevin Matras now has more of his own money in one particular stock than in any other. He believes in its short-term profit potential and also in its prospects to more than double by 2019. Today he reveals and explains his surprising move in a new Special Report.
Download it free >>